Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614414 | 0.86 | GSR (0.44) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL1168277 | 0.86 | GSR (0.44) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL1168594 | 0.86 | GSR (0.44) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL1167729 | 0.86 | GSR (0.44) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL6052844 | 0.83 | GSR (0.37) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL1234805 | 0.82 | GSR (0.38) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL1168908 | 0.78 | GSR (0.42) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL17843610 | 0.75 | GSR (0.48) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL22209237 | 0.75 | GSR (0.48) | GSRDPP4DPP7DPP8DPP9 | |
| SCHEMBL1168273 | 0.75 | GSR (0.42) | GSRDPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | claimed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | US | claimed |
| EP-1898930-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | Dynamis Therapeutics, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20070021357-A1 | Treatment of inflammatory conditions | DYNAMIS THERAPEUTICS, INC. | 2007-01-25 | — | — | US | claimed |
| WO-2006138609-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-1021175-B1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8431527-B2 | Methods for alleviating deleterious effects of 3-deoxyglucosone | FOX CHASE CANCER CENTER (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-6004958-A | ADMINISTERING FRUCTOSE-LYSINE-3-PHOSPHATE KINASE INHIBITOR; INHIBITING DEOXYGLUCOSONE BY-PRODUCT FORMATION | FOX CHASE CANCER CENTER (US) | 1999-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | GSR 2465/4885DPP4 2947/4885DPP7 3044/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | GSR 1409/4885DPP4 253/4885DPP7 208/4885 |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DPM1, G6PD, UGGT1 | GSR 1409/4885DPP4 253/4885DPP7 208/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | GSR 1409/4885DPP4 253/4885DPP7 208/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | GSR 138/4885DPP4 81/4885DPP7 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.